Relevant bibliographies by topics / Fractional exhaled nitric oxide (FENO) suppression test

Academic literature on the topic 'Fractional exhaled nitric oxide (FENO) suppression test'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fractional exhaled nitric oxide (FENO) suppression test.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Fractional exhaled nitric oxide (FENO) suppression test"

1

Khurana, Sandhya. "Use of fractional exhaled nitric oxide to guide the treatment of asthma and chronic cough." Journal of Precision Respiratory Medicine 5, no. 1 (December 1, 2022): 1–4. http://dx.doi.org/10.2500/jprm.2022.5.220003.

Full text
Abstract:
Fractional exhaled nitric oxide (FeNO) is a breath biomarker that is easy to perform at the point of care in individuals 5 years or older. Elevated FeNO levels indicate increased type 2 airway inflammation, specifically increased interleukin 4/13 activity. Recent guidelines have made recommendations on the utility of FeNO measurement in the diagnosis and management of asthma. Measurement of FeNO is recommended as an adjunct to the evaluation process in patients with suspected asthma in whom the diagnosis of asthma is uncertain based on clinical presentation, spirometry, and bronchodilator challenge testing. Elevated FeNO levels are associated with an increased risk of asthma exacerbation, and FeNO suppression test can help differentiate “difficult” from “severe” asthma. High FeNO levels can predict response to anti-inflammatory therapies, including corticosteroids and certain biologics. FeNO measurement also has value in evaluation of chronic cough with increased levels suggesting a corticosteroid responsive condition such as cough-variant asthma or eosinophilic bronchitis.
APA, Harvard, Vancouver, ISO, and other styles
2

Gemicioglu, Bilun, Benan Musellim, Ismail Dogan, and Kasim Guven. "Fractional Exhaled Nitric Oxide (FeNo) in Different Asthma Phenotypes." Allergy & Rhinology 5, no. 3 (January 2014): ar.2014.5.0099. http://dx.doi.org/10.2500/ar.2014.5.0099.

Full text
Abstract:
Fractioned exhaled nitric oxide (FeNO) is a noninvasive marker of inflammation in asthmatic patients. FeNO can be used to monitor airway inflammation, but individual responses make tailored interventions based on FeNO difficult. The correlation between the asthma control test (ACT), FEV1, and FeNO was evaluated in this study to ascertain the correct usage of FeNO with different asthma phenotypes regarding their control, allergy, comorbidity, obesity, age, smoking status, and severity. ACT, pulmonary function, and FeNO in 416 asthmatic patients on combined therapy were retrospective evaluated. Correlations between these parameters and the FeNO levels in different asthma phenotypes were calculated. In the study population, FeNO was 31.8 ± 28.5 parts per billion (ppb), FEV1 was 83.4 ± 19% and ACT was 19 ± 5.2. ACT scores were negatively correlated with FeNO (r = −0.31; p = 0.002). FeNO was different in patients with positive and negative skin-prick test (p < 0.05), with and without allergic rhinitis (p < 0.01), and with and without allergic conjunctivitis (p < 0.01). Significantly higher FeNO levels were found with logistic regression analysis only in patients with a history of emergency room visits (ERVs) (p = 0.024). The rate of the ERV of the patients with an ACT score more than or equal to 20 and with a FeNO value of more than 35 ppb was 22.9%, but with a FeNO value of less than 35 ppb was 6.5% (p = 0.004). Allergy and allergic comorbidities may lead to an increase in FeNO levels. Patients with a history of ERV have markedly higher FeNO levels, although they have an ACT score more than or equal to 20.
APA, Harvard, Vancouver, ISO, and other styles
3

Jang, Yoon Young, and Ji Young Ahn. "Evaluation of Fractional Exhaled Nitric Oxide in Pediatric Asthma and Allergic Rhinitis." Children 8, no. 1 (December 23, 2020): 3. http://dx.doi.org/10.3390/children8010003.

Full text
Abstract:
Fractional exhaled nitric oxide (FeNO) is a non-invasive test for evaluating the degree of airway inflammation and for the diagnosis, evaluation, and treatment of asthma. We attempted to measure FeNO levels in Korean children with asthma and determine its cutoff value for diagnosing asthma. We enrolled 176 children and adolescents between the ages of 5 and 18 years, who visited for the evaluation of chronic cough, shortness of breath, and wheezing. Among them, 138 patients who underwent skin prick tests or inhalation Immuno CAP (UniCAP; Pharmacia, Uppsala, Sweden) tests for allergy testing together with a pulmonary function test were included. FeNO was measured using a NIOX MINO (Aerocrine AB, Solna, Sweden) instrument according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. There were 29 patients with asthma, 43 with rhinitis, and 38 with asthma and allergic rhinitis. In the asthma group, FeNO levels significantly correlated with total immunoglobulin E (r = 0.572, p < 0.001), but did not show significant correlation with pulmonary function test parameters (forced vital capacity—FVC, forced expiratory volume in one second—FEV1, FEV1/FVC) or PC20 (provocative concentration of methacholine causing a 20% fall in FEV1). The FeNO cutoff values obtained in the asthma and asthma rhinitis groups were 16.5 ppb and 18.5 ppb, respectively. Hence, we provide a FeNO cutoff value according to the presence or absence of rhinitis in pediatric patients with asthma.
APA, Harvard, Vancouver, ISO, and other styles
4

Akbay, Nilay Orak, Zuleyha Bingol, Esen Kiyan, Ekrem Bilal Karaayvaz, Ahmet Kaya Bilge, Halim Issever, and Gulfer Okumus. "Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study." Clinical and Applied Thrombosis/Hemostasis 24, no. 3 (April 10, 2017): 483–88. http://dx.doi.org/10.1177/1076029617702243.

Full text
Abstract:
Pulmonary hypertension (PH) is a fatal disease although significant improvements in treatment are achieved. Easily implemented and noninvasive prognostic techniques are needed while following-up these patients. The aim was to investigate the role of fractional exhaled nitric oxide (FeNO) in follow-up for patients with PH. In this longitudinal study, patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH) who were seen in PH Outpatient Clinic, Istanbul Faculty of Medicine, Istanbul University, were enrolled in the study. Echocardiography, 6-minute walking test, brain natriuretic peptide, and FeNO measurements were performed, and World Health Organization functional class was evaluated to all patients at baseline, and third, and sixth months. Right-heart catheterization and pulmonary function tests at the time of diagnosis were recorded. The study comprised 31 patients (23 women, 8 men; mean age: 53.4 ± 17.1 years) with PAH (n = 19) and CTEPH (n = 12) and 80 healthy controls. Patients with PH had lower FeNO values than the control group (16.5 ppb vs 19.8 ppb; P < .05). Fractional exhaled nitric oxide values did not change during follow-up and did not correlate with other follow-up measures except tricuspid annular plane systolic excursion values. Fractional exhaled nitric oxide was higher in the idiopathic PAH subgroup at baseline and at third month than patients with PAH associated with other diseases. Fractional exhaled nitric oxide did not change in patients who had clinical deterioration. As a conclusion; Patients with PH had lower FeNO values than healthy controls, but FeNO did not change significantly during follow-up. Large-scale studies with prolonged follow-up periods are needed to understand the role of FeNO in the follow-up of the patients with PH.
APA, Harvard, Vancouver, ISO, and other styles
5

Mosquera, Ricardo A., Cheryl L. Samuels, Tomika S. Harris, Aravind Yadav, S. Shahrukh Hashmi, Melissa S. Knight, and Mary Kay Koenig. "Decreased Exhaled Nitric Oxide Levels in Patients with Mitochondrial Disorders." Open Respiratory Medicine Journal 7, no. 1 (July 26, 2013): 67–70. http://dx.doi.org/10.2174/1874306401307010067.

Full text
Abstract:
Background: Nitric oxide (NO) deficiency may occur in mitochondrial disorders (MD) and can contribute to the pathogenesis of the disease. It is difficult and invasive to measure systemic nitric oxide. NO is formed in the lungs and can be detected in expired air. Currently, hand-held fractional exhaled nitric oxide (FeNO) measurement devices are available enabling a fast in-office analysis of this non-invasive test. It was postulated that FeNO levels might be reduced in MD. Methods: Sixteen subjects with definite MD by modified Walker criteria (4 to 30 years of age) and sixteen healthy control subjects of similar age, race and body mass index (BMI) underwent measurement of FeNO in accordance with the American Thoracic Society guidelines. Results: Sixteen patient-control pairs were recruited. The median FeNO level was 6.5 ppm (IQR: 4-9.5) and 10.5 ppm (IQR: 8-20.5) in the MD and control groups, respectively. In 13 pairs (81%), the FeNO levels were lower in the MD cases than in the matched controls (p=0.021). Eleven (69%) cases had very low FeNO levels (≤7ppm) compared to only 1 control (p=0.001). All cases with enzymatic deficiencies in complex I had FeNO ≤7ppm. Conclusions: Single-breath exhaled nitric oxide recordings were decreased in patients with MD. This pilot study suggests that hand-held FeNO measurements could be an attractive non-invasive indicator of MD. In addition, measurement of FeNO could be used as a parameter to monitor therapeutic response in this population.
APA, Harvard, Vancouver, ISO, and other styles
6

Duong-Quy, Sy, Thuy Nguyen-Thi-Dieu, Khai Tran-Quang, Tram Tang-Thi-Thao, Toi Nguyen-Van, Thu Vo-Pham-Minh, Quan Vu-Tran-Thien, et al. "Study of Nasal Fractional Exhaled Nitric Oxide (FENO) in Children with Allergic Rhinitis." Sinusitis 5, no. 2 (October 8, 2021): 123–31. http://dx.doi.org/10.3390/sinusitis5020013.

Full text
Abstract:
(1) Background: Exhaled nitric oxide (NO) has been considered as a biomarker of airway inflammation. The measurement of fractional exhaled NO (FENO) is a valuable test for assessing local inflammation in subjects with allergic rhinitis (AR). (2) Objective: To evaluate (a) the correlation between nasal FENO with anthropometric characteristics, symptoms of AR and nasal peak flows in children without and with AR; and (b) the cut-off of nasal FENO for diagnosis of AR in symptomatic children. (3) Methods: The study was a descriptive and cross-sectional study in subjects with and without AR < 18 years old. All clinical and functional characteristics of the study subjects were recorded for analysis. They were divided into healthy subjects for the control group and subjects with AR who met all inclusion criteria. (4) Results: 100 subjects (14 ± 3 years) were included, including 32 control subjects and 68 patients with AR. Nasal FENO in AR patients was significantly higher than in control subjects: 985 ± 232 ppb vs. 229 ± 65 ppb (p < 0.001). In control subjects, nasal FENO was not correlated with anthropometric characteristics and nasal inspiratory or expiratory peak flows (IPF or EPF) (p > 0.05). There was a correlation between nasal FENO and AR symptoms in AR patients and nasal IPF and EPF (p = 0.001 and 0.0001, respectively). The cut-off of nasal FENO for positive AR diagnosis with the highest specificity and sensitivity was ≥794 ppb (96.7% and 92.6%, respectively). (5) Conclusion: The use of nasal FENO as a biomarker of AR provides a useful tool and additional armamentarium in the management of allergic rhinitis.
APA, Harvard, Vancouver, ISO, and other styles
7

Barański, Kamil, Krzysztof Kocot, Edyta Melaniuk-Wolny, Elwira Zajusz-Zubek, and Małgorzata Kowalska. "The Effect of Physical Activity on Spirometry and Fractional Exhaled Nitric Oxide in Adolescents—Longitudinal Study." Sustainability 13, no. 11 (May 21, 2021): 5770. http://dx.doi.org/10.3390/su13115770.

Full text
Abstract:
Highly intense and chronic physical activity may cause an inflammatory process in the airways. The inflammatory process in the respiratory system can be measured either by the spirometry test and exhaled nitric oxide. The aim of this study was to assess the effect of different levels of physical activity on fractional exhaled nitric oxide (FeNO) and spirometry parameters. Fifty healthy students (volunteers) who were participating in physical activity classes (low level of physical activity) and attending sports training (high and medium level of physical activity) completed two indoor exercise training two to three weeks apart. FeNO was measured twice, at baseline and after 45–60 min of exercise followed by spirometry. There was no significant difference in FeNO values and spirometry parameters between the groups with different physical activity. However, students with the highest level of physical activity presented a higher and significant variance of FeNO levels in comparison to students with lower physical activity. Healthy young adults (professional sportspersons) have a higher internal variability of FeNO. That suggests the initial ongoing inflammatory process in the airways. Any level of physical activity does not affect spirometry parameters before and after training in young healthy adults.
APA, Harvard, Vancouver, ISO, and other styles
8

Gao, Qingbo, Qiaozhen Wu, Fei Li, and Cheng Chen. "Fractional exhaled nitric oxide could identify early spirometry change in clinically suspected asthma patients without airway obstruction." European Journal of Inflammation 19 (January 2021): 205873922110041. http://dx.doi.org/10.1177/20587392211004110.

Full text
Abstract:
Fractional exhaled nitric oxide (FeNO) has been proposed as a non-invasive biomarker for allergic inflammation seen in asthma. The aim of this study was to assess the ability of FeNO to discriminate spirometry and lung volume measurements between those with and without airway obstruction among subjects with clinically suspected asthma. A retrospective study was conducted. Diagnostic evaluations including spirometry and FeNO testing (NO electrochemical equipment: NIOX VERO; Aerocrine AB, Solna, Sweden) were performed in all subjects. Airway obstruction was defined according to the Standardization of Spirometry of the American Thoracic Society (ATS)/European Respiratory Society (ERS), and 2014 recommendations of the Chinese National Guidelines of Pulmonary Function Test. It was used the Student t test for analysis of continuous variables and the χ2 test for analysis of discrete variables including FeNO levels and lung function metrics. Of the 138 subjects with clinically suspected asthma, airway obstruction was found in 61. There was no significant difference in the mean FeNO levels among subjects with or without airway obstruction ( p = 0.241) among un-selected subjects. Likewise, there was no difference in the FeNO levels between aged (>50 years) and younger subjects (⩽50 years) ( p = 0.804). A significant proportion of subjects had a normal FeNO level (<25 part per billion, ppb) in spite of having airway obstruction (39/138), 25 had an elevated FeNO level (⩾25 ppb) in spite of having no airway obstruction (25/138). Additionally, the airway-obstructed subjects with increased FeNO level had comparable spirometry to those with normal FeNO level ( p > 0.05). However, among subjects without airway obstruction, the forced expiratory volume in 1 s (FEV1)/predicted (pred), maximal expiratory flow at 25% of forced vital capacity (FVC) (MEF25%)/pred, maximal expiratory flow at 50% of FVC (MEF50%)/pred and maximum mid-expiratory flow (MMEF)/pred were significantly lower in the FeNO ⩾ 25 ppb group compared to those in the FeNO < 25 ppb group. These analyses indicated that increased FeNO levels could help to determinate early spirometry change within clinically suspected asthma subjects without airway obstruction. It is highlighted the importance of FeNO as a phenotype associated with an increased risk of airway obstruction in some subjects in this study.
APA, Harvard, Vancouver, ISO, and other styles
9

Hetherington, KJ, RW Costello, and LG Heaney. "S2 Fractional exhaled nitric oxide (feno) suppression to identify non-adherence in difficult asthma." Thorax 71, Suppl 3 (November 15, 2016): A4.2—A5. http://dx.doi.org/10.1136/thoraxjnl-2016-209333.8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Galiniak, Sabina, David Aebisher, and Marta Rachel. "Exhaled nitric oxide in smokers and former smokers with chronic obstructive pulmonary disease." Medical Science Pulse 14, no. 1 (June 30, 2020): 1–16. http://dx.doi.org/10.5604/01.3001.0014.2399.

Full text
Abstract:
Background: Measurement of fractional exhaled nitric oxide (FeNO) is a useful technique for detection of eosinophilic airway inflammation and assessment of efficiency of corticosteroid treatment in patents with respiratory disease. Generally studies agree that measurement of FeNO is a useful non-invasive biomarker in patients with chronic obstructive pulmonary disease (COPD), however, there are reports that do not confirm such a relationship between FeNO and COPD. Aim of the study: The main objective of this study was to investigate FeNO levels in Polish patients with COPD compared to healthy controls. As a secondary objective, we assessed the influence of smoking on FeNO levels in healthy patients, and patients with COPD. Material and methods: FeNO concentration was measured using an electrochemical analyzer in healthy non-smokers (n=21), healthy smokers (n=25), and former smokers with COPD (n=30) and smokers with COPD (n=38). General characteristics, hematological variables and serum biochemical parameters were also obtained and analyzed using the Kruskal-Wallis test. Results: FeNO measurement revealed significantly reduced NO levels in healthy smokers compared to healthy non-smokers, former smokers with COPD and smokers with COPD (median [range]: 14 [6–17] vs. 21 [15–29], 25 [15–53], and 19 [11–32] ppb, respectively, p<0.001). Moreover, we found increased FeNO levels in ex-smokers with COPD compared with smokers with COPD (p<0.05). No associations between FeNO and other analyzed parameters were found. Conclusions: Levels of FeNO, measured by with an electrochemical analyzer, were elevated among patients with COPD compared to healthy non-smoking controls. Moreover, our study confirms that smoking results in a reduction in FeNO concentration in both healthy patients and patients with COPD.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "Fractional exhaled nitric oxide (FENO) suppression test"

1

Faruqi, Shoaib, Joanne Thompson, Terry Robinson, Karen Watkins, Helena Cummings, Nicola Jackson, Anoop Prakash, and Michael Crooks. "Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes?" In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

See, Y. Y., E. C. Y. Chow, M. Crooks, M. Robinson, K. Watkins, F. Turner, J. Thompson, S. Faruqi, and E. C. Y. Chow. "Utility of “smart” inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?" In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.3865.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Issever, Halim, Hulya Dogan Tiryaki, Nefise Seker, Elif Ezirmik, and Iklim Gurcan. "0092 A critical evaluation of fractional exhaled nitric oxide (feno) and pulmonary function test levels in bakery and plastics workers." In Eliminating Occupational Disease: Translating Research into Action, EPICOH 2017, EPICOH 2017, 28–31 August 2017, Edinburgh, UK. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/oemed-2017-104636.70.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mokaddem Mohsen, Salma, Sana Ben Jemaa, Dorra El Guiche, Khadija Ayed, Islem Latifa Hadj Khalifa, and Saloua Ben Khamsa Jameleddine. "Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)?" In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Faruqi, S., J. Thompson, K. Watkins, H. Cummings, N. Jackson, A. Prakash, and MG Crooks. "P12 Suppression of fractional exhaled nitric oxide with directly observed inhaled corticosteroid therapy: is it a useful test in routine clinical practice?" In British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2017. http://dx.doi.org/10.1136/thoraxjnl-2017-210983.154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Fractional exhaled nitric oxide (FENO) suppression test' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography